Home › NDC Lookup › RxCUI directory › RxCUI 1604544

1.5 ML insulin glargine 300 UNT/ML Pen Injector [Toujeo] — RxCUI 1604544

Name: 1.5 ML insulin glargine 300 UNT/ML Pen Injector [Toujeo] (RxCUI 1604544)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 1604544 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1604544

Official name1.5 ML insulin glargine 300 UNT/ML Pen Injector [Toujeo]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known as1.5 ML Toujeo 300 UNT/ML Pen Injector; Toujeo 300 UNT/ML in 1.5 ML Pen Injector; Toujeo 300 UNT/ML 1.5 ML Prefilled Pen

FDA products mapped3

Package NDCs mapped5

Reported Medicaid activity (SDUD)96,057 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Insulin Glargine (rDNA origin) Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Insulin glargine is a long-acting insulin — it's designed to provide a slow, steady background level of insulin over the course of the day, rather than a quick spike like short-act...
What exactly is insulin glargine and why did my doctor prescribe it instead of regular insulin?
You can take insulin glargine at any time of day that works for your routine — morning, evening, whenever. The key is to take it at the same time every single day. Consistency help...
Does it matter what time of day I take my injection?

📖 Read our full Insulin Glargine (rDNA origin) Injection guide →

🕸️ Concept Web — How 1.5 ML insulin glargine 300 UNT/ML Pen Injector... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 1.5 ML insulin glargine 300 UNT/ML Pen Injector [Toujeo] RxCUI 1604544 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Insulin glargine 274783 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Toujeo 1604540 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Insulin glargine Pen Injector 1653497 SCDF
- Insulin glargine Injectable Product 1157459 SCDG
- Insulin glargine Pen Injector [Toujeo] 1653506 SBDF
- Toujeo Injectable Product 1604543 SBDG
- Pen Injector 1649571 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 1.5 ML insulin glargine 300 UNT/ML Pen Injector 1604539 SCD
- Insulin glargine 300 UNT/ML 1604538 SCDC
- Insulin glargine 300 UNT/ML [Toujeo] 1604541 SBDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

1.5 ML insulin glargine 300 UNT/ML Pen Injector SCD · 1604539
Insulin glargine 300 UNT/ML SCDC · 1604538
Insulin glargine Pen Injector SCDF · 1653497
Insulin glargine Injectable Product SCDG · 1157459

Brand-Name Concepts

Insulin glargine 300 UNT/ML [Toujeo] SBDC · 1604541
Insulin glargine Pen Injector [Toujeo] SBDF · 1653506
Toujeo Injectable Product SBDG · 1604543
Toujeo BN · 1604540

📦 FDA Products & Package NDCs

3 products · 5 package NDCs

5 package NDCs map to RxCUI 1604544 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00024-5869-00	1 SYRINGE in 1 CARTON (0024-5869-00) / 1.5 mL in 1 SYRINGE	TOUJEO	Sanofi-Aventis U.S. LLC	2015-02-15
00024-5869-03	3 SYRINGE in 1 CARTON (0024-5869-03) / 1.5 mL in 1 SYRINGE...	TOUJEO	Sanofi-Aventis U.S. LLC	2015-02-15
00024-5871-01	1 SYRINGE in 1 CARTON (0024-5871-01) / 3 mL in 1 SYRINGE	TOUJEO Max	Sanofi-Aventis U.S. LLC	2018-03-26
00024-5871-02	2 SYRINGE in 1 CARTON (0024-5871-02) / 3 mL in 1 SYRINGE (0...	TOUJEO Max	Sanofi-Aventis U.S. LLC	2018-03-26
50090-2193-00	3 SYRINGE in 1 CARTON (50090-2193-0) / 1.5 mL in 1 SYRINGE	TOUJEO	A-S Medication Solutions	2015-10-26

Observed labelers: Sanofi-Aventis U.S. LLC (4) · A-S Medication Solutions (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.

Per ml · median

$91.3004

Range $91.2671–$91.3337 · middle 50% $91.2838–$91.3171 · 2 NDCs

Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.